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making;
Individualised
medicinehave been reported. We performed a pooled analysis of prospective European impact studies
to generate robust data on impact of use in different clinical subgroups.
Methods: The analysis included four studies (French, German, Spanish, and British) in ERþ
human epidermal growth factor receptor 2enegative breast cancer patients (nZ 527). Node-
positive patients were excluded.
Results: The analysis demonstrated that treatment recommendations changed in 32% of pa-
tients post-testing; chemotherapy recommendation rate decreased from 55% to 34%. Change
rates in the individual studies ranged from 30% to 37%. The highest change rates were in pa-
tients originally recommended chemotherapy and in grade II tumours; there was no subgroup
without a treatment recommendation change. Notably, 31% of patients with an intermediate
Recurrence Score result had a treatment recommendation change suggesting that testing pro-
vides actionable information in this group. With the exception of the German study (where
chemotherapy rates remained high [41%] post-testing), between-study variability in treatment
recommendations decreased post-testing (chemotherapy: from 36e52% to 26e29%; hormonal
therapy: from 48e64% to 71e74%). Physicians’ confidence regarding treatment recommenda-
tions improved in all the studies after testing.
Conclusion: Recurrence Score testing led to changes in adjuvant chemotherapy use in approx-
imately a third of patients, to an overall reduced chemotherapy use, and to more homoge-
neous decision making.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Only a modest proportion of patients with oestrogen
receptor positive (ERþ) human epidermal growth factor
receptor 2 (HER2)enegative early breast cancer benefit
from adjuvant chemotherapy [1]. Since currently used
traditional markers are prognostic but not predictive of
chemotherapy benefit, there is substantial over-
treatment. The 21-gene Recurrence Score assay (the
Oncotype DX Breast Recurrence Score Assay;
Genomic Health, Inc., Redwood City, CA) is a vali-
dated prognosticator (in ERþ node-negative and node-
positive early breast cancer patients) that provides in-
dependent prognostic information to traditional mea-
sures and has been shown to predict adjuvant
chemotherapy benefit when tested in patients previously
included in phase III clinical trials that randomised
patients to hormonal therapy (HT) alone versus che-
mohormonal therapy (CHT) [1e6].
Importantly, results from four recently published/
presented studies now confirm the available prospective
retrospective validation data. The prospective phase III
TAILORx adjuvant trial demonstrated that in node-
negative hormone receptor (HR)þ HER2-negative pa-
tients (n Z 1626) with low (10) Recurrence Score re-
sults treated with HT alone, distant-recurrence risk at 5
years was very low (0.7%) [7]. The prospective phase III
WSG Plan B trial in patients with node-positive or high-
risk node-negative HRþ HER2-negative disease showed
that in this patient population too, the distant-recur-
rence risk is very low in patients (n Z 348) with
Recurrence Score results 11 and HT alone (3-year
event-free survival of 98.3%) [8]. The third studyevaluated a large cohort (n Z 2028) of patients for
whom treatment decisions incorporated the assay in
real-life clinical practice [9]. It reported a 5-year rate of
distant recurrence of 0.8% in patients with low Recur-
rence Score results (<18) treated with HT (2% chemo-
therapy use), a 3.2% rate in patients with intermediate
scores (18e30) (25% chemotherapy use), and a 10.6%
rate in patients with high scores (31) (88% chemo-
therapy use) [9]. The fourth study was a prospectively
defined analysis of the Surveillance, Epidemiology, and
End Results registry which was electronically supple-
mented with Recurrence Score results. It reported sur-
vival data only and demonstrated excellent 5-year breast
cancer-specific survival in >21,000 node-negative HRþ
HER2-negative breast cancer patients with low Recur-
rence Score results (99.6%) [10].
The Recurrence Score assay is incorporated in major
international guidelines such as the American Society of
Clinical Oncology (ASCO), National Comprehensive
Cancer Network (NCCN), European Society for
MedicalOncology, and StGallen as a tool to help estimate
prognosis and the magnitude of chemotherapy benefit
[11e14].
Despite inclusion in all major international guide-
lines, less than 20% of patients in Europe have access to
the Recurrence Score assay through national reim-
bursement. Absence of outcome data from prospective
studies as well as from real-life studies in patient pop-
ulations that are using the assay to guide treatment
decisions has been stated as the main cause for lack of
reimbursement in many countries. Treatment recom-
mendations in ERþ early breast cancer in European
countries vary owing to different therapeutic traditions/
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able, an increase in access and reimbursement is likely.
Therefore, it is relevant to assess the impact of using the
assay in different patient populations and countries.
Here, we performed a pooled analysis in order to
generate as robust data as possible regarding the impact
of the assay on adjuvant treatment recommendations in
node-negative ERþ, HER2-negative breast cancer in
available prospective European decision impact studies.
We evaluated the association between traditional pa-
rameters and assay-driven treatment recommendation
changes and also compared treatment recommendations
between study countries pre- and post-assay.2. Methods
2.1. Patient population
The analysis included four European prospective studies
finalised to date, according to the best knowledge of the
authors. These similarly designed studies investigated
the impact of Recurrence Score testing on clinical de-
cisions in France, Germany, Spain, and the United
Kingdom (UK) [15e18]. In these studies, consecutive
patients with no contraindications to chemotherapy
were enrolled, adjuvant treatment recommendations of
the treating physician pre- and post-Recurrence Score
testing were recorded, and the treating physicians
completed questionnaires regarding their confidence in
their treatment recommendations before/after testing.
All patients included in the final pooled analysis
(n Z 527) were node negative, ERþ, HER2 negative
and underwent Recurrence Score testing as per study
protocols. Node-positive patients, patients with micro-
metastases, and those with no available Recurrence
Score results were excluded (nZ 151) to provide a more
homogeneous study population.2.2. Statistical analysis
Analysis of variance/chi-squared tests were used to
assess continuous/categorical parameters across studies.
McNemar’s test was used to assess whether the change
(from pre- to post-testing) in the proportion of patients
with CHT and HT recommendations was significant.
Wilcoxon signed-rank test was used to assess whether
the change (from pre- to post-testing) in physicians’
confidence was significant.
Using logistic regression analysis, the probability of a
treatment recommendation change was modelled as a
function of the Recurrence Score category (as defined by
Paik et al. [2]), age (<55, 55 years; this cutoff value
was chosen as a proxy for menopausal status), tumour
size (2, >2 cm; i.e. T1 versus T2/T3), grade (IeIII),
progesterone receptor (PR) status, and Ki-67 levels
(<20%, 20%). Patients with missing data wereexcluded from the analysis. Stepwise regression analysis
was performed to determine whether interactions be-
tween the evaluated covariates and the Recurrence Score
result should be included in the model.
3. Results
3.1. Study patients
The analysis included 565 patients (French study, 83;
Spanish study, 107; UK study, 131; and German study,
244). The patient populations were similar with respect
to age and PR status and differed with respect to tumour
size and grade (p < 0.0001, both variables) (Table 1).
3.2. Recurrence Score distribution
A wide range of Recurrence Score results was observed
in the pooled cohort (Fig. 1) with a median (range) of 16
(0e81) and a mean (SD) of 18.1 (10.1) (p Z 0.19 for
comparison across studies). The distribution of Recur-
rence Score categories differed across the studies
(p Z 0.031) (Table 1).
The distribution of these Recurrence Score cate-
gories was similar in younger and older patients (<55,
55 years) and in patients with smaller and larger (2,
>2 cm) tumours (p Z 0.37 and p Z 0.081, respec-
tively); the distribution differed by grade (p < 0.0001)
(Fig. 2).
3.3. Changes in treatment recommendations
Treatment recommendations before and after Recur-
rence Score testing were available for 527 patients. Pre-
testing, 45.4% were recommended CHT and 54.6% HT
(Table 2). Overall, 31.9% (95% confidence interval [CI],
27.9e35.9%) had a recommendation change post-
testing. Of the CHT-recommended patients (pre-
testing), 48.1% (95% CI, 41.8e54.5%) were recom-
mended HT post-testing; of the HT-recommended pa-
tients (pre-testing), 18.4% (95% CI, 13.9e22.9%) were
recommended CHT post-testing. After knowing the
assay results, the proportion of CHT-recommended
patients decreased to 33.6% (net reduction: 26%; rela-
tive reduction: 38%); the proportion of HT-
recommended patients increased to 66.4% (Table 2;
p < 0.0001). Knowing the assay result impacted treat-
ment recommendations for patients in all Recurrence
Score grade, age, and tumour size groups (Table 2).
Significant changes in the proportion of CHT- and HT-
recommended patients were also observed in the low
Recurrence Score group as defined in the TAILORx
study (<11) [7] (Table 2). These changes were aligned
with the Recurrence Score results: a decrease in CHT
recommendations was observed in low Recurrence
Score patients and an increase in high Recurrence Score
patients. Upon dividing the intermediate Recurrence
Table 1
Patient and tumour characteristics.
French
study
n Z 83
Spanish
study
n Z 107
UK
study
n Z 131
German
study
n Z 244
All studies
N Z 565
Age, yearsa
Mean (SD) 55 (10) 54 (11) 56 (9) 56 (11) 56 (10)
Median (range) 55 (33e79) 53 (29e78) 55 (34e72) 56 (25e85) 55 (25e85)
Age, n (%)b
<55 years 26 (31.3) 39 (36.4) 29 (22.1) 77 (31.6) 171 (30.3)
55 years 57 (68.7) 68 (63.6) 102 (77.9) 167 (68.4) 394 (69.7)
Tumour size, cmc
Mean (SD) NA NA 2.0 (1.2) 2.1 (1.2) 2.1 (1.2)
Median (range) NA NA 1.7 (0.5e6.0) 1.8 (0.5e9.0) 1.8 (0.5e9.0)
Tumour size, n (%)d
2 cm 67 (80.7) 91 (85.0) 85 (64.9) 154 (63.1) 397 (70.3)
>2 cm 15 (18.1) 16 (15.0) 46 (35.1) 90 (36.9) 167 (29.6)
Unknown 1 (1.2) e e e 1 (0.2)
Tumour grade, n (%)e
I 6 (7.2) 37 (34.6) 23 (17.6) 33 (13.5) 99 (17.5)
II 67 (80.7) 46 (43.0) 86 (65.6) 188 (77.0) 387 (68.5)
III 10 (12.0) 20 (18.7) 22 (16.8) 23 (9.4) 75 (13.3)
Unknown e 4 (3.7) e e 4 (0.7)
Progesterone receptor status, n (%)f
Negative 12 (14.5) 16 (15.0) 15 (11.5) 28 (11.5) 71 (12.6)
Positive 70 (84.3) 90 (84.1) 113 (86.3) 216 (88.5) 489 (86.5)
Unknown 1 (1.2) 1 (0.9) 3 (2.3) d 5 (0.9)
Recurrence Score category, n (%)g
Low (<18) 47 (56.6) 62 (57.9) 72 (55.0) 131 (53.7) 312 (55.2)
Intermediate (18e30) 32 (38.6) 35 (32.7) 37 (28.2) 95 (38.9) 199 (35.2)
High (31) 4 (4.8) 10 (9.3) 22 (16.8) 18 (7.4) 54 (9.6)
UK, United Kingdom; SD, standard deviation; ANOVA, analysis of variance.
ap Z 0.44 (ANOVA).
bp Z 0.099 (chi-squared test).
cp Z 0.66 (ANOVA). Detailed tumour size information was not available for the French and Spanish studies.
dp < 0.0001 (chi-squared test).
ep Z 0.74 (chi-squared test).
fp Z 0.031 (chi-squared test).
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Fig. 1. Distribution of Recurrence Score results for the entire cohort (NZ 565). Recurrence Score groups were [2]: blue, Recurrence Score
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increase in CHT recommendation was observed in both
subgroups (statistically significant in the former
[p Z 0.0094] and trending in the latter [p Z 0.058])
(Table 2).
The data from the individual studies were similar to
those of the pooled analysis with the proportions of
patients with a treatment recommendation change
ranging from 29.9 to 36.6% (Table 3).
The changes in treatment recommendations (an
overall decreased CHT and increased HT use) were
statistically significant in the French, UK, and German
studies (p < 0.0001, p Z 0.020, and p Z 0.047,
respectively) and trending (p Z 0.086) in the Spanish
study. With the exception of the German study, which
was characterised by a relatively high proportion of
CHT-recommended patients post-testing (41%), the
between-study variability in the proportions of CHT-
and HT-recommended patients decreased post-testing
(CHT: from 36.4e52.4% to 25.6e28.7%; HT: from
47.6e63.6% to 71.3e74.4%) (Fig. 3).
In a univariate analysis, the association between the
Recurrence Score category and change in treatment
recommendation was significant for both a change from
HT to CHT (odds ratio [OR], 30.5 for high Recurrence
Score versus intermediate and low categories combined;
95% Wald CI, 6.5e142.6; p < 0.0001) and from CHT to
HT (OR, 34.0 for low Recurrence Score versus inter-
mediate and high categories combined; 95% Wald CI,
16.6e69.6; p < 0.0001).A logistic regression analysis was used to model the
probability of changing treatment recommendation as a
function of the Recurrence Score category, age (<55,
55 years), tumour size (2, >2 cm), tumour grade
(IeIII), PR status (positive, negative), and the in-
teractions thereof, for patients who were initially rec-
ommended HT as well as for patients who were initially
recommended CHT. The probability could not be
modelled using all Recurrence Score categories because
of the prominent impact of the high and low Recurrence
Score results in patients who were initially recom-
mended CHT and HT, respectively. Therefore, we
combined the intermediate and high categories for the
analysis of CHT to HT change and the low and inter-
mediate categories for the analysis of HT to CHT
change. In a stepwise regression analysis, the interaction
of the Recurrence Score category and the other cova-
riates was determined to be non-significant. For patients
who were initially recommended CHT, having a low
(versus high/intermediate) Recurrence Score result was
associated with significantly higher odds of CHT to HT
change, as was having a grade I or II tumours, being
PR-positive, and having smaller tumours. For patients
who were initially recommended HT, having a high
(versus low/intermediate) Recurrence Score result was
associated with significantly higher odds of HT to CHT
change, as was being younger, having grade III tumours,
and being PR-negative (Table 4). In a logistic regression
analysis using all the aforementioned covariates and Ki-
67 levels (which were available only for 241 patients),
Table 2
The impact of knowing the Recurrence Score result on treatment recommendation for the entire cohort, by Recurrence Score category, grades,
age groups, and tumour size.
HT (post-testing) CHT (post-testing) Total
All patients (N Z 527)a
HT (pre-testing) 235 (44.6%) 53 (10.1%) 288 (54.6%)
CHT (pre-testing) 115 (21.8%) 124 (23.5%) 239 (45.4%)
Total 350 (66.4%) 177 (33.6%) 527 (100%)
Low [2] Recurrence Score (score values <18) (nZ 293)a
HT (pre-testing) 176 (60.1%) 1 (0.3%) 177 (60.4%)
CHT (pre-testing) 98 (33.4%) 18 (6.1%) 116 (39.6%)
Total 274 (93.5%) 19 (6.5%) 293 (100%)
Intermediate [2] Recurrence Score (score values: 18e30) (nZ 185)b
HT (pre-testing) 57 (30.8%) 41 (22.2%) 98 (53.0%)
CHT (pre-testing) 17 (9.2%) 70 (37.8%) 87 (47.0%)
Total 74 (40.0%) 111 (60.0%) 185 (100%)
High [2] Recurrence Score (score values 31) (nZ 49)c
HT (pre-testing) 2 (4.1%) 11 (22.4%) 13 (26.5%)
CHT (pre-testing) 0 (0%) 36 (73.5%) 36 (73.5%)
Total 2 (4.1%) 47 (95.9%) 49 (100%)
TAILORx-based low Recurrence Score (score values <11) (nZ 99)a
HT (pre-testing) 65 (65.7%) 0 (0%) 65 (65.7%)
CHT (pre-testing) 32 (32.3%) 2 (2.0%) 34 (34.3%)
Total 97 (98.0%) 2 (2.0%) 99 (100%)
Intermediate [2] group: Sub-analysis. Scores of 18e25 (nZ 155)d
HT (pre-testing) 51 (32.9%) 33 (21.3%) 84 (54.2%)
CHT (pre-testing) 15 (9.7%) 56 (36.1%) 71 (45.8%)
Total 66 (42.6%) 89 (57.4%) 155 (100%)
Intermediate [2] group: sub-analysis. Scores of 26e30 (nZ 30)e
HT (pre-testing) 6 (20.0%) 8 (26.7%) 14 (46.7%)
CHT (pre-testing) 2 (6.7%) 14 (46.7%) 16 (53.3%)
Total 8 (26.7%) 22 (73.3%) 30 (100%)
Grade I (nZ 91)f
HT (pre-testing) 67 (73.6%) 2 (2.2%) 69 (75.8%)
CHT (pre-testing) 12 (13.2%) 10 (11.0%) 22 (24.2%)
Total 79 (86.8%) 12 (13.2%) 91 (100%)
Grade II (n Z 362)a
HT (pre-testing) 155 (42.8%) 43 (11.9%) 198 (54.7%)
CHT (pre-testing) 92 (25.4%) 72 (19.9%) 164 (45.3%)
Total 247 (68.2%) 115 (31.8%) 362 (100%)
Grade III (nZ 70)g
HT (pre-testing) 11 (15.7%) 8 (11.4%) 19 (27.1%)
CHT (pre-testing) 10 (14.3%) 41 (58.6%) 51 (72.9%)
Total 21 (30.0%) 49 (70.0%) 70 (100%)
<55 years (nZ 164)a
HT (pre-testing) 59 (36.0%) 16 (9.8%) 75 (45.7%)
CHT (pre-testing) 50 (30.5%) 39 (23.8%) 89 (54.3%)
Total 109 (66.5%) 55 (33.5%) 164 (100%)
55 years (nZ 363)h
HT (pre-testing) 176 (48.5%) 37 (10.2%) 213 (58.7%)
CHT (pre-testing) 65 (17.9%) 85 (23.4%) 150 (41.3%)
Total 241 (66.4%) 122 (33.6%) 363 (100%)
2 cm (nZ 369)i
HT (pre-testing) 191 (51.8%) 42 (11.4%) 233 (63.1%)
CHT (pre-testing) 69 (18.7%) 67 (18.2%) 136 (36.9%)
Total 260 (70.5%) 109 (29.5%) 369 (100%)
>2 cm (nZ 157)a
HT (pre-testing) 44 (28.0%) 11 (7.0%) 55 (35.0%)
CHT (pre-testing) 46 (29.3%) 56 (35.7%) 102 (65.0%)
Total 90 (57.3%) 67 (42.7%) 157 (100%)
CHT, chemohormonal therapy; HT, hormonal therapy.
ap < 0.0001; bp Z 0.0016; cp Z 0.0009; dp Z 0.0094; ep Z 0.058; fp Z 0.0075; gp Z 0.64; hp Z 0.0056; ip Z 0.010.
All for change from CHT to HT and from HT to CHT; McNemar’s test.
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Table 3
The impact of knowing the Recurrence Score result on treatment
recommendation by study.
HT
(post-testing)
CHT
(post-testing)
Total
German study (n Z 244)a
HT (pre-testing) 99 (40.6%) 28 (11.5%) 127 (52.0%)
CHT (pre-testing) 45 (18.4%) 72 (29.5%) 117 (48.0%)
Total 144 (59.0%) 100 (41.0%) 244 (100%)
French study (nZ 82)b
HT (pre-testing) 35 (42.7%) 4 (4.9%) 39 (47.6%)
CHT (pre-testing) 26 (31.7%) 17 (20.7%) 43 (52.4%)
Total 61 (74.4%) 21 (25.6%) 82 (100%)
Spanish study (nZ 107)c
HT (pre-testing) 56 (52.3%) 12 (11.2%) 68 (63.6%)
CHT (pre-testing) 22 (20.6%) 17 (15.9%) 39 (36.4%)
Total 78 (72.9%) 29 (27.1%) 107 (100%)
UK study (nZ 94)d
HT (pre-testing) 45 (47.9%) 9 (9.6%) 54 (57.4%)
CHT (pre-testing) 22 (23.4%) 18 (19.1%) 40 (42.6%)
Total 67 (71.3%) 27 (28.7%) 94 (100%)
UK, United Kingdom; CHT, chemohormonal therapy; HT, hormonal
therapy.
ap Z 0.047; bp < 0.0001; cp Z 0.086; dp Z 0.020.
All for change from CHT to HT and from HT to CHT; McNemar’s
test.
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significant covariate in patients who were initially rec-
ommended CHT and none of the covariates were found
to be significant in patients who were initially recom-
mended HT.
In addition, we evaluated the correlation between Ki-
67 and the Recurrence Score results in the 241 patients
for whom both values were available and found a
moderate Pearson correlation coefficient of 0.46.Fig. 3. The impact of knowing the Recurrence Score results on treatm
CI, confidence interval; CHT, chemohormonal therapy.3.4. The impact of testing on physicians’ confidence
regarding treatment recommendations
The four evaluated studies differed in the scale used to
assess physicians’ confidence regarding treatment rec-
ommendations. Therefore, these data were not pooled,
and the analysis was performed for each study sepa-
rately. Between 33.0% and 60.2% of physicians in the
evaluated studies reported increased, 33.0e52.4% re-
ported no change, and 6.8e14.9% reported decreased
confidence regarding treatment recommendations
(Fig. 4). In all studies, knowing the Recurrence Score
result was associated with a significant improvement in
physicians’ confidence regarding treatment recom-
mendations (p < 0.01, all studies). Knowing the
Recurrence Score result increased the physicians’
confidence in the final treatment recommendation,
regardless of whether the treatment recommendation
changed or not.4. Discussion
This pooled analysis of four prospective European
studies demonstrated that despite differences in thera-
peutic traditions between countries, Recurrence Score
testing significantly impacted adjuvant treatment rec-
ommendations and physicians’ confidence about treat-
ment recommendations in node-negative ERþ, HER2-
negative breast cancer, with an overall change rate of
32% and a relative reduction in chemotherapy use of
38%. These results are consistent with findings from
studies performed worldwide [19e26], all showing a sig-
nificant impact of testing on adjuvant treatment decisions
with a change in approximately one third of patients.ent recommendations by Recurrence Score category [2] and study.
Table 4
Odds ratios for changing treatment recommendations (logistic regression analysis).
Effect Odds ratio 95% Wald confidence limits p-value
Change from CHT to HT
Recurrence Score group [2]:
low versus int/high (combined)
48.5 19.7e119.6 < 0.0001
Age: <55 years versus 55 years 0.92 0.40e2.1 0.84
Tumour size: 2 cm versus >2 cm 2.7 1.1e6.7 0.029
Tumour grade:
Grade I versus II 1.4 0.3e6.0 0.64
Grade I versus III 10.0 1.7e58.0 0.010
Grade II versus III 7.1 2.2e22.4 0.0008
PR status: negative versus positive 0.078 0.017e0.36 0.001
Change from HT to CHT
Recurrence Score group [2]: high
versus low/intermediate (combined)
22.8 4.5e117.0 0.0002
Age: <55 years versus 55 years 2.3 1.0e5.0 0.042
Tumour size: 2 cm versus >2 cm 1.4 0.55e3.6 0.48
Tumour grade:
Grade I versus II 0.12 0.026e0.51 0.004
Grade I versus III 0.069 0.011e0.44 0.004
Grade II versus III 0.60 0.18e2.0 0.41
PR status: negative versus positive 5.6 2.2e14.4 0.0003
CHT, chemohormonal therapy; HT, hormonal therapy; PR, progesterone receptor.
Interactions between the Recurrence Score and the other covariates were found to be non-significant. The analysis included 236 patients for the
CHT to HT analysis and 286 patients for the CHT to HT analysis (patients with missing data were excluded).
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erogeneous in the different studies with substantial dif-
ferences in the proportion of patients with low,
intermediate, and high Recurrence Score results being
recommended chemotherapy. Post-testing, the between-
study variability decreased and treatment recommen-
dations became more homogeneous, suggesting that
broad use of the assay may reduce heterogeneity in
treatment decisions. Health-economic (HE) studies from
all evaluated markets show that broad use of the assay is
cost effective (reviewed by Zanotti et al. [27]). None-
theless, from a medical as well as HE perspective, it is of
interest to understand in which patients the assay has34.1% 
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Fig. 4. The impact of knowing the Recurrence Score result on pthe highest utility. When assessing treatment recom-
mendation change rates by subgroups, the highest
change rate was seen in patients originally recommended
chemotherapy (48.1%), grade II (37.3%), and younger
patients (40.4%). Treatment recommendation changes
were seen in a similar range of patients regardless of
tumour size (2, >2 cm). Thus, it can be argued that
from a HE perspective, the most important patient
subgroups in which to use the assay include those
originally recommended chemotherapy and those with
grade II tumours. From a medical perspective, it is
important to note that all the clinical categories listed
above had a clinically relevant treatment33.0% 
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use of the assay to patients originally recommended
chemotherapy means that some patients that could be
identified by the assay as having a high likelihood of
benefitting from chemotherapy will not receive a treat-
ment that could reduce their distant-recurrence risk.
It is sometimes argued that an intermediate Recur-
rence Score result is unhelpful. However, in our study,
approximately a third (31.4%) of patients with inter-
mediate results had a treatment recommendation
change, demonstrating that intermediate results pro-
vide clinically actionable information. This is likely
related to the fact that the Recurrence Score result is
given on a continuous scale. Indeed, when the inter-
mediate Recurrence Score group was divided into those
with 18e25 and 26e30 Recurrence Score results, CHT
recommendation rate increased more pronouncedly in
the latter subgroup (relative increase of 37% versus
25%). The present data are consistent with studies from
the United States and Israel showing that decisions in
patients with intermediate results are determined pri-
marily based on whether the result is low or high
(within the intermediate range) with a strong increase
in chemotherapy recommendations in patients with
scores >25 and that other traditional factors such as
grade, tumour size, and age also matter [9,28,29].
Notably, results from the Clalit study [9] where pa-
tients were not randomized to chemotherapy or no
chemotherapy indicate that patients with Recurrence
Score results of 25 or less without other high-risk fea-
tures have little or no benefit from chemotherapy,
although it should be noted that the results of TAI-
LORx on the role of chemotherapy in intermediate
Recurrence Score patients are pending. Ki-67 is used in
many countries as a marker relevant for treatment
decisions despite recent data highlighting substantial
issues with reproducibility and data showing that the
marker is not predictive of chemotherapy benefit
[30,31]. In this pooled analysis, many but not all pa-
tients had Ki-67 assessments available. The correlation
between Ki-67 and the Recurrence Score result was
modest, consistent with data from the WSG Plan B
study [32].
In conclusion, our findings demonstrate that the
Recurrence Score has a substantial impact on treatment
recommendations with an overall significant reduction
in chemotherapy use. The consistency of the results from
different countries underlines the utility of the Recur-
rence Score. The highest change rates were seen in pa-
tients originally recommended chemotherapy, in
younger patients, and in patients with grade II, but there
was no subgroup of patients that did not have a clini-
cally relevant rate of change in treatment recommen-
dations. Limiting the use of the Recurrence Score assay
to the subgroups of patients with the highest change rate
may be of HE interest due to cost effectiveness and can
even be associated with cost savings. From a medicalperspective, a broad use of the assay has the advantage
of both reducing chemotherapy in those with minimal if
any benefit, as well as identifying a smaller proportion
of patients that are likely to have a substantial benefit
from chemotherapy. A broad use of the assay will also
reduce the substantial heterogeneity of treatment rec-
ommendations currently seen when using traditional
markers.
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